Bronchopulmonary dysplasia: Changes in pathogenesis, epidemiology and definition

Seminars in Neonatology

Volumn 8, Issue 1, 2003, Pages 63-71

  Bancalari, Eduardo ^a   Claure, Nelson ^a   Sosenko, Ilene R S ^a  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

BPD definition; BPD epidemiology; BPD pathogeneis; Bronchopulmonary; Dysplasia; Mechanical ventilation; Neonatal chronic lung disease; Oxygen therapy; Patent ductus arteriosus; Prematurity

Indexed keywords

OXYGEN;

ARTIFICIAL VENTILATION; CHRONIC LUNG DISEASE; CLINICAL FEATURE; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST; DISEASE CLASSIFICATION; DISEASE COURSE; DYSPNEA; GESTATIONAL AGE; HUMAN; INCIDENCE; INFANT; INFLAMMATION; LUNG ALVEOLUS; LUNG CAPILLARY; LUNG DYSPLASIA; OXYGEN THERAPY; OXYGEN TOXICITY; PATENT DUCTUS ARTERIOSUS; PATHOGENESIS; PERINATAL INFECTION; PREMATURITY; RESPIRATORY FAILURE; REVIEW; RISK FACTOR; SYMPTOM;

EID: 0037301116     PISSN: 10842756     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1084-2756(02)00192-6     Document Type: Review

References (47)

1. Northway WH Jr., Rosen RC, Porter DY. Pulmonary disease following respirator therapy of hyaline membrane disease: bronchopulmonary dysplasia. N Engl J Med 1967;276:357-68.
2. Rojas MA, Gonzalez A, Bancalari E, Claure N, Poole C, Silva-Neto G. Changing trends in the epidemiology and pathogenesis of neonatal chronic lung disease. J Pediatr 1995;126:605-10.
3. Gonzalez A, Sosenko IRS, Chandar J, Hummler H, Claure N, Bancalari E. Influence of infection on patent ductus arteriosus and chronic lung disease in premature infants weighting 1000 grams or less. J Pediatr 1996;128:470-8.
4. Taghizadeh A, Reynolds ED. Pathogenesis of bronchopulmonary dysplasia following hyaline membrane disease. Am J Pathol 1976;82:241-64.
5. Jobe AH, Bancalari E. Bronchopulmonary dysplasia. NICHD-NHLBI-ORD Workshop. Am J Respir Crit Care Med 2001;163:1723-9.
6. Palta M, Gabbert D, Weinstein MR, Peters ME. Multivariate assessment of traditional risk factors for chronic lung disease in very low birth weight neonates. J Pediatr 1991;119:285-92.
7. Gerdes JS, Yoder MC, Douglas SD, Paul M, Harris MC, Polin RA. Tracheal Lavage and plasma fibronectin: relationship to respiratory distress syndrome and development of bronchopulmonary dysplasia. J Pediatr 1986;108:601-6.
8. Groneck P, Gotze-Speer B, Oppermann M, Eiffert H, Speer CP. Association of pulmonary inflammation and increased microvascular permeability during the development of bronchopulmonary dysplasia: a sequential analysis of inflammatory mediators in respiratory fluids of high-risk preterm neonates. Pediatrics 1994;93:712-8.
9. Hannaford K, Todd DA, Jeffery H, John E, Byth K, Gilbert GL. Role of Ureaplasma urealyticum in lung disease of prematurity. Arch Dis Child Fetal Neonatal Ed 1999;81:F162-7.
10. 1-proteinase inhibitor activity in tracheal aspirates during respiratory distress syndrome: role of inflammation in the pathogenesis of bronchopulmonary dysplasia. J Clin Investig 1983;72:656-66.
11. Pierce MR, Bancalari E. The role of inflammation in the pathogenesis of bronchopulmonary dysplasia. Pediatr Pulmonol 1995;19:371-8.
12. Speer CP, Ruess D, Harms K, Herting E, Gefeller O. Neutrophil elastase and acute pulmonary damage in neonates with severe respiratory distress syndrome. Pediatrics 1993;91:794-9.
13. Stenmark KR, Eyzaguirre M, Westcott JY, Henson PM, Murphy RC. Potential role of eicosanoids and PAF in the pathophysiology of bronchopulmonary dysplasia. Am Rev Respir Dis 1987;136:770-2.
14. Walti H, Tordet C, Gerbaut L, Saugier P, Moriette G, Relier JP. Persistent elastase/proteinase inhibitor imbalance during prolonged ventilation of infants with BPD: evidence for the role of nosocomial infections. Pediatr Res 1989;26:351-5.
15. Watterberg KL, Carmichael DF, Gerdes JS, Werner S, Backstrom C, Murphy S. Secretory leukocyte protease inhibitor and lung inflammation in developing bronchopulmonary dysplasia. J Pediatr 1994;125:264-9.
16. Watterberg KL, Demers LM, Scott SM, Murphy S. Chorioamnionitis and early lung inflammation in infants in whom bronchopulmonary dysplasia develops. Pediatrics 1996;97:210-5.
17. Brown ER, Stark A, Sosenko I, Lawson EE, Avery ME. Bronchopulmonary dysplasia: possible relationship to pulmonary edema. J Pediatr 1978;92:982-4.
18. Hazinski TA, Blalock WA, Engelhardt B. Control of water balance in infants with bronchopulmonary dysplasia: role of endogenous vasopressin. Pediatr Res 1988;23:86-8.
19. Merritt TA, Harris JP, Roghmann K, Wood B, Campanella V, Alexson C. Early closure of patent ductus arteriosus in very low-birth weight infants: a controlled trial. J Pediatr 1981;99:281-6.
20. Spitzer AR, Fox WW, Delivoria-Papadopoulos M. Maximum diuresis: a factor in predicting recovery from respiratory distress syndrome and the development of bronchopulmonary dysplasia. J Pediatr 1981;98:476-9.
21. Tammela OK, Koivisto ME. Fluid restriction for preventing bronchopulmonary dysplasia? Reduced fluid intake during the first weeks of life improves the outcome of low-birth-weight infants. Acta Paediatr 1992;81:207-12.
22. Van Marter LJ, Leviton A, Allred EN, Pagno M, Kuban KC. Hydration during the first days of life and the risk of bronchopulmonary dysplasia in low birth weight infants. J Pediatr 1990;116:942-9.
23. Gerhardt T, Bancalari E. Lung compliance in newborns with patent ductus arteriosus before and after surgical ligation. Biol Neonote 1980;38:96-105.
24. Deneke SM, Lynch BA, Fanburg BL. Effect of low protein diets or feed restriction on rat lung glutathione and oxygen toxicity. J Nutr 1985;115:726-32.
25. Sosenko IRS, Kinter MT, Roberts RJ. Nutritional issues in chronic lung disease of premature infants. In: Bland RJ, Coalson JJ, editors. Chronic lung disease in early infancy. New York: Marcel Dekker 2000;285-96.
26. Tyson JE, Wright LL, Oh W, Kennedy KA, Mete L, Ehrenkranz RH. Vitamin A supplementation for extremely-low-birth-weight infants. N Engl J Med 1999;340:1962-8.
27. Smyth JA, Tabachnik E, Duncan WJ, Reilly BJ, Levison H. Pulmonary function and bronchial hyper-reactivity in long-term survivors of bronchopulmonary dysplasia. Pediatrics 1981;68:336-40.
28. Goldman SL, Gerhardt T, Sonni R, Feller R, Tapia JL, Bancalari E. Early prediction of chronic lung disease by pulmonary function testing. J Pediatr 1983;102:613-7.
29. Gerhardt T, Hehre D, Feller R, Reifenberg L, Bancalari E. Serial determination of pulmonary function in infants with chronic lung disease. J Pediatr 1987;110:448-56.
30. Greenspan JS, DeGiulio PA, Bhutaniv K. Airway reactivity as determined by a cold air challenge in infants with bronchopulmonary dysplasia. J Pediatr 1989;114:452-4.
31. Watterberg KL, Scott SM. Evidence of early adrenal insufficiency in babies who develop bronchopulmonary dysplasia. Pediatrics 1995;95:120-5.
32. Watterberg KL, Gerdes JS, Gifford KL, Lin HM. Prophylaxis against early adrenal insufficiency to prevent chronic lung disease in premature infants. Pediatrics 1999;104:1258-63.
33. Watterberg KL, Scott SM, Backstrom C, Gifford KL, Cook KL. Links between early adrenal function and respiratory outcome in preterm infants: airway inflammation and patent ductus arteriosus. Pediatrics 2000;15:320-4.
34. 1 interteukin-1β, and interleukin-8) and the risk for the development of bronchopulmonary dysplasia. Am J Obstet Gynecol 1997;177:825-30.
35. Varsila E, Hallman M, Venge P, Andersson S. Closure of patent ductus arteriosus decreases pulmonary myeloperoxidase in premature infants with respiratory distress syndrome. Biol Neonote 1995;67:167-71.
36. Koyama N, Ogawa Y, Kamiya K, Eguchi H, Tanaka T, Takasaki J et al. Increased platelet activating factor in the tracheal aspirates from neonates with patent ductus arteriosus. Clin Chim Acta 1993;215:73-9.
37. del Moral T, Claure N, VanBuskirk S, Bancalari E. Duration of patent ductus arteriosus as a risk factor for bronchopulmonary dysplasia. Pediatr Res 2001;49:282A.
38. Lemons JA, Bauer CR, Oh W, Korones SB, Papile LA, Stoll BJ. Very low birth weight outcomes of the National Institute of Child Health and Human Development Neonatal Research Network, January 1995 through December 1996. Pediatrics 2001;107:1-8.
39. Parker RA, Pagano M, Allred EN. Improved survival accounts for most, but not all, of the increase in bronchopulmonary dysplasia. Pediatrics 1992;90:663-8.
40. Collaborative European Multicenter Study Group. Surfactant replacement therapy for severe neonatal respiratory distress syndrome: an international randomized clinical trial. Pediatrics 1990;82:683-90.
41. Kendig JW, Notter RH, Cox C, Aschner JL, Benn S, Bernstein RM. Surfactant replacement therapy at birth: final analysis of a clinical trial and comparisons with similar trials. Pediatrics 1988;82:756-62.
42. Jobe AH. Pulmonary surfactant therapy. N Engl J Med 1993;328:861-8.
43. Schwartz RM, Luby AM, Scanlon JW, Kellogg RJ. Effect of surfactant on morbidity, mortality, and resource use in newborn infants weighing 500 to 1500 g. N Engl J Med 1994;330:1476-80.
44. Bancalad E, Abdenour GE, Feller R, Gannon J. Bronchopulmonary dysplasia: clinical presentation. J Pediatr 1979;95:819-23.
45. Shennan AT, Dunn MS, Ohlsson A, Lennox K, Hoskins EM. Abnormal pulmonary outcomes in premature infants: prediction from oxygen requirements in the neonatal period. Pediatrics 1988;82:527-32.
46. Ellsbury DL, Acarregui MJ, McGuinness GA, Klein JM. Variability in the use of supplemental oxygen for bronchopulmonary dysplasia. J Pediatr 2002;140:247-9.
47. Walsh-Sukys M, Zadelt A, Fanaroff A. Development of a physiologic definition of bronchopulmonary dysplasia. Pediatr Res 2001;49:314A.